• If you are wondering whether Tango Therapeutics at around US$31.56 is still offering value or has run too far ahead, you are not alone.
• The stock has seen sharp recent moves, with returns of 46.8% over the last week, 37.1% over the past month and a very large gain year to date, as well as over the last 1 year and 3 years.
• Recent news flow around Tango Therapeutics has focused on its position in the biotech space and how investors are reacting to its progress in oncology drug development. This context helps explain why the stock has been on many watchlists as sentiment around the company continues to shift.
• Even after these moves, Tango Therapeutics carries a valuation score of 2 out of 6, so it only screens as undervalued on a couple of checks. The next sections will walk through those methods and finish with a way to think about valuation that goes beyond the standard ratios and models.

Tango Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Tango Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today to estimate what the business could be worth right now. It is essentially asking what those future dollars are worth in today’s terms.

For Tango Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $142.7 million. Analyst inputs then feed into projections, with free cash flow estimated at $103 million in 2030, and Simply Wall St extrapolating further years based on those earlier estimates.

Pulling all those projected cash flows together and discounting them back results in an estimated intrinsic value of about $53.10 per share. Compared with the recent share price around $31.56, the DCF output suggests the stock trades at a discount of about 40.6%, which indicates it screens as undervalued on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Tango Therapeutics is undervalued by 40.6%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Tango Therapeutics Price vs Book

For companies that are still building towards consistent profitability, the P/B ratio is often a practical yardstick because it compares the market value of the stock with the accounting value of net assets on the balance sheet. It helps you see how much investors are willing to pay for each dollar of book value, with higher ratios often reflecting stronger growth expectations or a higher perceived risk profile.

Tango Therapeutics currently trades on a P/B of about 11.66x. This sits well above the Biotechs industry average of about 2.36x and above the peer group average of about 3.85x. This indicates the stock is priced at a premium relative to both its sector and closer comparables. Simply Wall St’s “Fair Ratio” is a proprietary estimate of what the P/B might be, given factors like earnings growth, industry, profit margins, market cap and company specific risks.

Because it blends these fundamentals, the Fair Ratio can be more tailored than a simple industry or peer comparison. In this case, the Fair Ratio is not available, so it is not possible to state whether the current 11.66x P/B suggests the stock is overvalued, undervalued, or about right on this measure alone.

Result: ABOUT RIGHT

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Tango Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a tool that lets you attach a clear story about Tango Therapeutics to your numbers, including your assumed fair value and your expectations for future revenue, earnings and margins.

A Narrative connects what you believe about the company to a forecast, and then to a fair value estimate that you can directly compare with the current share price to help you decide whether the stock looks attractive, expensive or somewhere in between.

On Simply Wall St, Narratives are available on the Community page and are designed so that any investor can adjust key assumptions, see the fair value update in real time when new news or earnings arrive, and quickly check if their view still lines up with the market price.

For example, some Tango Therapeutics investors may set very optimistic assumptions that point to a much higher fair value than today’s price, while others may use more cautious assumptions that lead to a far lower fair value, showing how different Narratives can coexist around the same stock.

Do you think there's more to the story for Tango Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.